De Motu Cordis (DMC) Applauds ARS Pharma's FDA Approval of Neffy®, Expanding Patient Options to Needle-Free Epinephrine Delivery and Inspiring Confidence in Our Own Development Efforts

"We are pleased to see the approval of a needle-free treatment alternative," said Professor John Fraser, Founder, CMO, Director at DMC. "The approval of Neffy® strengthens the motivation for DMC and the broader drug delivery community to continue pushing the boundaries of innovation. We believe that faster epinephrine absorption via inhalation may prove to be a valuable alternative delivery mode not only for anaphylaxis but also for other emergency medical treatments." "We are pleased to see...

BRISBANE, Australia, 16/08/2024 (informazione.news - comunicati stampa - salute e benessere)

 said Professor John Fraser , Founder, CMO, Director at DMC. 

As we continue our development work, the approval of Neffy enhances our commitment to providing cutting-edge solutions to improve patient care and safety in critical situations.

 said Peter O'Neill , Chief Executive Officer, DMC.

DMC is actively developing , a proprietary drug-device inhaler platform technology specifically designed for emergency medicine in community settings. This platform is being tailored to be easily used by non-medically trained patients and caregivers, providing a more accessible and effective treatment option, particularly in situations where a rapid response is critical.

"DMC is a clinical stage pharma company". DMC was founded in Brisbane, Australia by Professor John Fraser , an Intensivist and groundbreaking clinician, researcher, and company founder. John is also founder of the Critical Care Research Group and is a co-founder of BIVACOR Pty Ltd. John co-founded the COVID-19 Critical Care Consortium that facilitated collecting over 35 million data points from ICU units worldwide and aided in the development of treatment pathways.

Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia . The majority of funding to date have been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices. A Series A financing round is planned for H1 2025, which will ideally be anchored by a US based VC.

View original content:https://www.prnewswire.co.uk/news-releases/de-motu-cordis-dmc-applauds-ars-pharmas-fda-approval-of-neffy-expanding-patient-options-to-needle-free-epinephrine-delivery-and-inspiring-confidence-in-our-own-development-efforts-302224197.html